Fanconi Anemia - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Fanconi Anemia - Pipeline Review, H2 2018’, provides an overview of the Fanconi Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fanconi Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fanconi Anemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fanconi Anemia

- The report reviews pipeline therapeutics for Fanconi Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Fanconi Anemia therapeutics and enlists all their major and minor projects

- The report assesses Fanconi Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Fanconi Anemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Fanconi Anemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Fanconi Anemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abeona Therapeutics Inc

Genethon SA

GlaxoSmithKline Plc

Novartis AG

Abeona Therapeutics Inc

Genethon SA

GlaxoSmithKline Plc

Novartis AG

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Fanconi Anemia - Overview

Fanconi Anemia - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Fanconi Anemia - Overview

Fanconi Anemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fanconi Anemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fanconi Anemia - Companies Involved in Therapeutics Development

Abeona Therapeutics Inc

Genethon SA

GlaxoSmithKline Plc

Novartis AG

Fanconi Anemia - Drug Profiles

ABO-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltrombopag olamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXG-34217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fancalen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy 1 for Fanconi Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate FANC-A for Fanconi Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate FANCA for Fanconi Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate FANCA Protein for Fanconi Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP-4039 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPL-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPL-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Fanconi Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-3025 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fanconi Anemia - Dormant Projects

Fanconi Anemia - Product Development Milestones

Featured News & Press Releases

Jul 26, 2018: Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator

Feb 24, 2016: Abeona Therapeutics to Present on CRISPR/CAS9 Technology Platform Progress at CRISPR Precision Gene Editing Congress

Oct 03, 2011: Experimental Drug Could Help Protect Some Cancer Patients From Radiation Side Effects, UPCI Researchers Find

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Fanconi Anemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Fanconi Anemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Fanconi Anemia - Pipeline by Abeona Therapeutics Inc, H2 2018

Fanconi Anemia - Pipeline by Genethon SA, H2 2018

Fanconi Anemia - Pipeline by GlaxoSmithKline Plc, H2 2018

Fanconi Anemia - Pipeline by Novartis AG, H2 2018

Fanconi Anemia - Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Fanconi Anemia, H2 2018 7

Number of Products under Development by Companies, H2 2018 8

Number ...

List of Figures

Number of Products under Development for Fanconi Anemia, H2 2018 7

Number of Products under Development by Companies, H2 2018 8

Number of Products under Development by Universities/Institutes, H2 2018 10

Number of Products by Targets, H2 2018 13

Number of Products by Stage and Targets, H2 2018 13

Number of Products by Mechanism of Actions, H2 2018 15

Number of Products by Stage and Mechanism of Actions, H2 2018 15

Number of Products by Routes of Administration, H2 2018 17

Number of Products by Stage and Routes of Administration, H2 2018 17

Number of Products by Molecule Types, H2 2018 19

Number of Products by Stage and Molecule Types, H2 2018 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports